Molecular Tagging of Pharmaceutical Drugs Utilizing Applied DNA’s Technology Published in Peer-Reviewed Journal
June 14 2019 - 8:00AM
Business Wire
PLOS ONE Publication Details Proprietary Method
to Distinguish Legitimate Pharmaceutical Drugs from Counterfeit
Products Including Counterfeit Opioids
Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today that
its scientific paper entitled, ‘Rapid authentication of
pharmaceuticals via DNA tagging and field detection’, has been
published in the June 2019 edition of PLOS ONE, detailing a novel
Physical-Chemical Identifier (PCID) to authenticate and track
legitimate pharmaceutical products through the pharmaceutical
supply chain.
The paper summarizes a study in which a pharmaceutical
manufacturer tagged acetaminophen capsules with
pharmaceutical-grade ink containing a unique DNA tag produced by
Applied DNA and its subsequent authentication. Study results
indicate that authentication can be performed reliably in a
laboratory or in the field utilizing easy to use portable devices,
and proves that Applied DNA’s SigNature® Molecular Tag can be
safely introduced onto the surface of a capsule in ordinary
pharmaceutical ink. The patent-pending, user-friendly method and
system showed the molecular tag can be read at any time after
simple, non-destructive swabbing.
“We believe DNA tagging of inks, coatings, and other ingredients
can be used in the pharmaceutical supply chain, securing
authenticity of an individual dose from the manufacturer, to the
distributor, and finally the pharmacy. Authentication is possible,
even when the product is separated from packaging, making it a
solid complement to serialization and a platform to be considered
as a weapon against today’s most difficult challenges, such as the
opioid crisis,” said Dr. James Hayward, president and CEO, Applied
DNA.
Drug overdose deaths in the United States are at unprecedented
levels, with synthetic opioids increasingly implicated in
overdoses, and the World Health Organization (WHO) estimates that
1-in-10 medical products circulating in low- and middle-income
countries is either substandard or falsified.
“Counterfeit drugs represent a large and growing problem for the
global pharmaceutical industry, and can lead to serious illness or
death. Publication of our methods and systems for molecular tagging
of pharmaceuticals is a seminal development in our industrial
deployment, and acceptance of our methods by scientific peers is a
welcome endorsement,” said Dr. Michael Hogan, vice president, Life
Sciences, Applied DNA.
About PLOS ONE
The world’s first multidisciplinary Open Access
journal, PLOS ONE accepts scientifically rigorous
research, regardless of novelty. PLOS ONE’s broad scope provides a
platform to publish primary research including interdisciplinary
and replication studies as well as negative results. The journal’s
publication criteria are based on high ethical standards and the
rigor of the methodology and conclusions reported.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN, and
warrants are listed under the symbol APDNW.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements
describe Applied DNA’s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
Applied DNA. Actual results could differ materially from those
projected due to its history of net losses, limited financial
resources, limited market acceptance, uncertainties relating to its
ability to maintain its NASDAQ listing, uncertainties relating to
receiving regulatory clearance from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies and
various other factors detailed from time to time in Applied DNA’s
SEC reports and filings, including our Annual Report on Form 10-K
filed on December 18, 2018 and our subsequent quarterly reports on
Form 10-Q filed on February 7, 2019 and May 9, 2019, and other
reports we file with the SEC, which are available at www.sec.gov.
Applied DNA undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date hereof to reflect the occurrence of
unanticipated events, unless otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190614005071/en/
investor contact: Sanjay M. Hurry, LHA Investor
Relations, 212-838-3777, shurry@lhai.comprogram
contacts: Dr. Michael Hogan, Vice President, Life
Sciences, 631-240-8820, mike.hogan@adnas.comweb:
www.adnas.comtwitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024